Ibnsina Pharma results, Q2 2023
Net profit, assets, equity and cash flow for Q2 2023, against the same period a year earlier, from the published financial statements.
Net profit214 millionEGP · +23.8% vs the same period a year earlier
Total assets18.55 billionEGP · +44.2% vs the same period a year earlier
Shareholders' equity1.45 billionEGP · +15.0% vs the same period a year earlier
Operating cash flow536 millionEGP · +48.1% vs the same period a year earlier
In short
- Ibnsina Pharma's net profit for Q2 2023 was about 214 million EGP, up +23.8% from 173 million EGP in Q2 2022.
- Total assets at the end of Q2 2023 were about 18.55 billion EGP, and shareholders' equity about 1.45 billion EGP.
- Operating cash flow for Q2 2023 was positive at 536 million EGP.
Key lines against the same period a year earlier
This periodQ2 2022Change
Net profit214 million173 million+23.8%
Gross profit2.63 billion1.62 billion+62.6%
Total assets18.55 billion12.86 billion+44.2%
Total liabilities17.1 billion11.6 billion+47.4%
Shareholders' equity1.45 billion1.26 billion+15.0%
Total liabilities and equity18.55 billion12.86 billion+44.2%
Operating cash flow536 million362 million+48.1%
Investing cash flow-280 million-1.38 billion+79.7%
Financing cash flow744 million1.09 billion−31.6%
Net change in cash406 million72.67 million+459.2%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Ibnsina Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy